Clinical Trial Update: YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

View source ↗

Summary

A terminated clinical trial update investigating the serum biomarker YKL-40 in patients with newly diagnosed stage III-IV ovarian epithelial, fallopian tube, or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Status: TERMINATED